Ashwani Verma
Stock Analyst at UBS
(2.05)
# 2,715
Out of 4,829 analysts
66
Total ratings
36.17%
Success rate
-3.91%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $137 → $152 | $120.43 | +26.21% | 8 | May 6, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $32.13 | +27.61% | 5 | May 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $55 → $48 | $35.65 | +34.64% | 2 | Apr 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $22 | $17.52 | +25.57% | 4 | Apr 28, 2025 | |
| ALKS Alkermes | Maintains: Neutral | $38 → $33 | $31.27 | +5.53% | 4 | Apr 28, 2025 | |
| CHRS Coherus BioSciences | Maintains: Neutral | $1.5 → $1.05 | $1.02 | +2.94% | 5 | Apr 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Buy | $145 → $179 | $103.58 | +72.81% | 6 | Mar 7, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $30 → $27 | $17.96 | +50.33% | 8 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $30 → $34 | $36.98 | -8.06% | 2 | Jan 28, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $22 → $14 | $9.59 | +45.99% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $475 | $310.80 | +52.83% | 4 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $59.50 | +91.60% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $20.56 | +162.65% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $110.16 | -4.68% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $33.36 | -16.05% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $32.38 | +150.15% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $77.77 | -91.00% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $8.96 | +33.93% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.61 | +2,346.98% | 1 | Oct 11, 2022 |
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $137 → $152
Current: $120.43
Upside: +26.21%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $32.13
Upside: +27.61%
Harmony Biosciences Holdings
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $35.65
Upside: +34.64%
ACADIA Pharmaceuticals
Apr 28, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $17.52
Upside: +25.57%
Alkermes
Apr 28, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $31.27
Upside: +5.53%
Coherus BioSciences
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.02
Upside: +2.94%
Jazz Pharmaceuticals
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $103.58
Upside: +72.81%
Teva Pharmaceutical Industries
Jan 30, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $17.96
Upside: +50.33%
Exelixis
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $34
Current: $36.98
Upside: -8.06%
Avadel Pharmaceuticals
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $9.59
Upside: +45.99%
Jan 8, 2025
Maintains: Buy
Price Target: $415 → $475
Current: $310.80
Upside: +52.83%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $59.50
Upside: +91.60%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $20.56
Upside: +162.65%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $110.16
Upside: -4.68%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $33.36
Upside: -16.05%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $32.38
Upside: +150.15%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $77.77
Upside: -91.00%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $8.96
Upside: +33.93%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.61
Upside: +2,346.98%